ManagedCareCGM.com Presents: Improving Quality Metrics and Reducing Cost of Care with Access to Real-Time Continuous Glucose Monitoring

Release Date: July 9, 2021
Expiration Date: January 31, 2023
Estimated Time to Complete Activity: 1.0 hour
Compatible with all modern browsers and mobile devices

Expert Faculty


	*Jeffrey Dunn, PharmD, MBA* Head of Clinical Pharmacy Berkshire Hathaway/Geico (formerly Haven, the Amazon, Berkshire Hathaway, JPMorgan Chase healthcare venture) Formerly VP, Clinical Strategy and Programs and Industry Relations Magellan Rx Management Click here for biography

	*Maria Lopes, MD, MS* Former Chief Medical Officer Magellan Health Click here for biography

	Janet B. McGill, MD, MA, FACE, FACP Professor of Medicine Washington University School of Medicine Click here for biography

	Vanita Pindolia, PharmD, BCPS, MBA Formerly Vice President, Ambulatory Clinical Pharmacy Programs_PCM Henry Ford Health System/Health Alliance Plan of Michigan Click here for biography

Target Audience

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.

Statement of Need/Program Overview
Diabetes remains a leading cost driver for payers and employers, characterized by insulin spend, hospitalization, and ER utilization. System-wide incentives to prescribe and access real-time continuous glucose monitoring (rtCGM) aligns with a patient-centered approach for managing diabetes-related outcomes and costs.

Pharmacy benefit coverage and access for CGM for appropriate sub-populations can confer immediate cost savings via channel efficiencies and lower acquisition costs. Furthermore, rtCGM has the potential to improve diabetes-specific performance and outcome measures in members with type 1, type 2, and gestational diabetes.

Educational Objectives
After completing this activity, the participant should be better able to:

Characterize the value of health technology and remote patient monitoring as part of a comprehensive management strategy for diabetes to improve glycemic outcomes
Discuss the positive impact of pharmacy coverage on payer management interventions, provider administrative burden, member experience and access, and overall cost of care
Review the potential of rtCGM to improve diabetes performance measures via hypoglycemia risk reduction, improved HbA1c, and reduced resource utilization with case scenarios (e.g., pregnancy; senior populations)

Accreditation Information

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional continuing Education (IPCE) credit for learning and change.

Physician Credit

Medical Education Resources designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources designates this enduring activity for a maximum of 1.0 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hours

Pharmacy Credit

Medical Education Resources (MER) designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Program Number – JA0003680-9999-21-057-H01-P
This activity is certified as Knowledge-based CPE.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be

Maria Lopes, MD, MS has nothing to disclose.

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Jeffrey Dunn, PharmD, MBA	Jeffrey Dunn, PharmD, MBA has nothing to disclose.
Maria Lopes, MD, MS	Maria Lopes, MD, MS has nothing to disclose.
Janet B. McGill, MD, MA, FACE, FACP	Grants/Research Support - Dexcom, Medtronic, Novo Nordisk Consulting fees (eg. Ad boards) - Bayer, Boehringer Ingelheim, Lilly, Metavant, Salix
Vanita Pindolia, PharmD, BCPS, MBA	Vanita Pindolia, PharmD, BCPS, MBA has nothing to disclose.

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

*Name of Content Manager*	*Reported Financial Relationship*
MER Content Managers	No financial relationships to disclose.
Impact Education, LLC Staff	No financial relationships to disclose.

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Dexcom Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period July 9, 2021 through February 28, 2023, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.